Elsa Krall
Q Therapeutics (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, Neutropenia and Cancer Infections, CRISPR and Genetic Engineering, Ubiquitin and proteasome pathways
Most-Cited Works
- → KRAS and YAP1 Converge to Regulate EMT and Tumor Survival(2014)749 cited
- → KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer(2017)155 cited
- → ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition(2017)126 cited
- → STAT3 acts through pre-existing nucleosome-depleted regions bound by FOS during an epigenetic switch linking inflammation to cancer(2015)42 cited
- → The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors(2024)40 cited
- → Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer(2017)28 cited
- → Abstract ND01: KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies(2022)6 cited
- → Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors(2024)1 cited
- → Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer(2017)1 cited
- → 205P Identification of novel bypasses of KRAS addiction(2016)